The Key Proteins of Dopaminergic Neurotransmission of Human Peripheral Blood Lymphocytes: Changed mRNA Level in Alcohol Dependence Syndrome

Bulletin of Experimental Biology and Medicine

Volumn 160, Issue 2, 2015, Pages 271-274

  Taraskina, A E ^a,b,c   Grunina, M N ^a   Zabotina, A M R ^a   Nasyrova, F ^c   Ivanov, M V ^c   Krupitsky, E M ^c   Schwartzman, A L ^a  

^a PETERSBURG NUCLEAR PHYSICS INSTITUTE   (Russian Federation)

^b PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^c N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

Author keywords

alcohol dependence syndrome; dopaminergic neurotransmission proteins; gene expression; peripheral blood lymphocytes; real time quantitative polymerase chain reaction

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; MESSENGER RNA; NUCLEAR RECEPTOR RELATED FACTOR 1; DOPAMINE RECEPTOR;

ADULT; ALCOHOLISM; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; PERIPHERAL LYMPHOCYTE; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; SAFETY; FEMALE; GENETICS; LYMPHOCYTE; METABOLISM; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ADULT; ALCOHOLISM; FEMALE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D3; RNA, MESSENGER; SYNAPTIC TRANSMISSION;

EID: 84957850684     PISSN: 00074888     EISSN: 15738221     Source Type: Journal    
DOI: 10.1007/s10517-015-3147-7     Document Type: Article

References (15)

1. A. E. Taraskina, S. N. Pchelina, M. L. Remizov, et al., Med. Genetika, 5, No. 10, 16-20 (2006).
2. A. E. Taraskina, S. N. Pchelina, E. M. Krupitsky, et al., Obozr. Psikhiatr. Med. Psikhol. im. V. M. Bekhtereva, No. 1, 62-70 (2009).
3. A. E. Taraskina, M. N. Morozova, N. V. Bychkova, et al., Ross. Immunol. Zh., 6, No. 3, 273-280 (2012).
4. F. R. Buttarelli, A. Fanciulli, C. Pellicano, and F. E. Pontieri, Curr. Neuropharmacol., 9, No. 2, 278-288 (2011).
5. J. W. Cave and H. Baker, Adv. Exp. Biol. Med., 651, 15-35 (2009).
6. C. Czermak, M. Lehofer, E. M. Wagner, et al., Addiction, 99, No. 2, 251-257 (2004).
7. D. M. Dick and T. Faroud, Alcohol. Clin. Exp. Res., 27, No. 5, 868-879 (2003).
8. A. L. Frederick and G. D. Stanwood, Dev. Neurosci., 31, Nos. 1-2, 7-22 (2009).
9. M. D. Köhnke, Biochem. Pharmacol., 75, No. 1, 160-177 (2008).
10. J. Langan, D. Martin, P. Shajahan, and D. J. Smith, BMC Psychiatry, 12, 214 (2012).
11. C. Missale, S. R. Nash, S. W. Robinson, et al., Physiol. Rev., 78, No. 1, 189-225 (1998).
12. J. Spence, T. Liang, T. Foroud, et al., Addict. Biol., 10, No. 1, 47-51 (2005).
13. B. Söderpalm, E. Löf, and M. Ericson, Pharmacopsychiatry, 42, Suppl. 1, S87-S94 (2009).
14. V. Vengeliene, A. Bilbao, A. Molander, and R. Spanagel, J. Pharmacol., 154, No. 2, 299-315 (2008).
15. T. I. Uzbay, Alcohol Alcohol, 47, No. 1, 33-41 (2012).